Deterioration of Performance Status during Palliative Radiotherapy Suggests a Significant Short Survival Duration: Indicating the Necessities for Considering Radiotherapy Discontinuation.

Hitoshi Maemoto, Kazuaki Kushi, Isoko Owan, Takuro Ariga, Joichi Heianna, Akihiro Nishie

Abstract read

In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Osteolytic Bone Metastasis: Different Radiotherapy Fractionation Schedules Compared Clinically and Radiographically.Current oncology (Toronto, Ont.) · 2024
Trial

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hitoshi MaemotoDivision of Radiation Oncology, NHO Okinawa Hospital, Okinawa 901-2214, Japan.ORCID 0000-0003-1235-5282

Kazuaki KushiDivision of Palliative Care, NHO Okinawa Hospital, Okinawa 901-2214, Japan.

Isoko OwanDivision of Pulmonary Medicine, NHO Okinawa Hospital, Okinawa 901-2214, Japan.

Takuro ArigaDepartment of Radiology, Graduate School of Medical Science, University of the Ryukyus, Okinawa 903-0213, Japan.

Joichi HeiannaDepartment of Radiology, Graduate School of Medical Science, University of the Ryukyus, Okinawa 903-0213, Japan.ORCID 0000-0002-8869-6924

Akihiro NishieDepartment of Radiology, Graduate School of Medical Science, University of the Ryukyus, Okinawa 903-0213, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Discontinuation of palliative radiotherapy due to a patient's declining general condition poses a clinical dilemma for palliative care physicians. This study aimed to investigate the survival duration of patients whose performance status (PS) deteriorated during palliative radiotherapy and inform decisions regarding early treatment discontinuation. We retrospectively analyzed data from patients referred from our institute's palliative care department who underwent ≥10 fractions of palliative radiotherapy between March 2017 and December 2021. PS was assessed using the Eastern Cooperative Oncology Group (ECOG) scale. Survival duration was calculated from the final day of palliative radiotherapy to death using the Kaplan-Meier method. A total of 35 patients underwent palliative radiotherapy. Seven (20%) experienced deterioration in ECOG PS during treatment. Their median survival duration was significantly shorter at 22 days (95% confidence interval: 1-94 days) compared to 125 days (95% confidence interval: 82-150 days) for the 28 patients whose PS remained stable (

Indexed as

NeoplasmsPalliative CareAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesWithholding Treatmentcancerpalliative careperformance statusradiotherapy

Identifiers

PMID38668036

DOI10.3390/curroncol31040133

PMCPMC11049355

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.